| Date Filed | Type | Description |
| 04/19/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/13/2017 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)] |
| 03/06/2017 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 03/02/2017 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 03/02/2017 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 03/02/2017 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement |
| 03/02/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/01/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 03/01/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership [Amend] |
| 03/01/2017 |
8-K
| Quarterly results |
| 03/01/2017 |
4
| PAPPAS ARTHUR M (10% Owner) has filed a Form 4 on CoLucid Pharmaceuticals, Inc. |
| 03/01/2017 |
4
| White Marvin L (Director) has filed a Form 4 on CoLucid Pharmaceuticals, Inc. |
| 03/01/2017 |
4
| Skwierczynski Raymond (Head,Pharmaceutical Operations) has filed a Form 4 on CoLucid Pharmaceuticals, Inc. |
| 03/01/2017 |
4
| Mathers Thomas P. (CEO) has filed a Form 4 on CoLucid Pharmaceuticals, Inc. |
| 03/01/2017 |
4
| Marengere Luc (10% Owner) has filed a Form 4 on CoLucid Pharmaceuticals, Inc. |
| 03/01/2017 |
4
| Lawton Alison Frances (Director) has filed a Form 4 on CoLucid Pharmaceuticals, Inc. |
| 03/01/2017 |
4
| Kuca Bernice (Head,Clin. and Reg. Operations) has filed a Form 4 on CoLucid Pharmaceuticals, Inc.|
Txns:
| Unknown transaction of 2,729 shares
@ $46.5, valued at
$126.9k
Disposed/sold 37,500 shares
@ $46.5, valued at
$1.7M
Disposed/sold 270,381 options to buy
@ $10, valued at
$2.7M
Disposed/sold 37,500 options to buy
@ $6.75, valued at
$253.1k
|
|
| 03/01/2017 |
4
| Hogan Linda C. (Head, Bus. Dev. and Strategy) has filed a Form 4 on CoLucid Pharmaceuticals, Inc. |
| 03/01/2017 |
4
| Dallas Matthew D (CFO) has filed a Form 4 on CoLucid Pharmaceuticals, Inc. |
| 03/01/2017 |
4
| CORRIGAN MARK (Director) has filed a Form 4 on CoLucid Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 8,114 options to buy
@ $3.79, valued at
$30.8k
Disposed/sold 8,897 options to buy
@ $6.24, valued at
$55.5k
|
|
| 03/01/2017 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities |
| 03/01/2017 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party [Amend] |
| 02/14/2017 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party [Amend] |
| 02/14/2017 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals |
| 02/10/2017 |
SC 13G/A
| CoLucid Pharmaceuticals, Inc. reports a 0% stake in CoLucid Pharmaceuticals, Inc. |
| 02/10/2017 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals [Amend] |
| 02/07/2017 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals [Amend] |
| 02/02/2017 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership |
| 01/31/2017 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements |
| 01/31/2017 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party |
| 01/27/2017 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership |
| 01/27/2017 |
3
| Form 3 - Initial statement of beneficial ownership of securities |
| 01/26/2017 |
SC 13G
| CoLucid Pharmaceuticals, Inc. reports a 7.3% stake in CoLucid Pharmaceuticals, Inc. |
| 01/18/2017 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party |
|